Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 3Terminated 1Not yet recruiting 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

Carboplatin 127Cisplatin 125Drug Therapy 117Bevacizumab 102Oxaliplatin 99Capecitabine 99Radiotherapy 97Gemcitabine 87tislelizumab 86Paclitaxel 86Cyclophosphamide 86Specimen Handling 80pembrolizumab 76toripalimab 68Magnetic Resonance Spectroscopy 65Fluorouracil 63Injections 62sintilimab 58Surgical Procedures, Operative 58anlotinib 53Docetaxel 52130-nm albumin-bound paclitaxel 50fludarabine 47Standard of Care 46Pemetrexed 45Immune Checkpoint Inhibitors 45Blood Specimen Collection 43Biopsy 43venetoclax 42Leucovorin 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × flumatinib × Clear all
NCT05367765 2022-05-10

A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 4 Not yet recruiting
2,400 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

Data powered by HemOnc (CC BY 4.0) Colophon âš¡